Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

Inclusion Criteria:

1. Informed consent of a parent(s) or legal guardian(s), as required by local laws.

2. Males and females, ages 3 months to <2 years old at Day 1.

3. Diagnosed with mild to moderate Atopic Dermatitis (AD) for at least 1 month durationprior to or at the screening visit.

4. Has AD involvement of ≥3% BSA at Day1.

5. In good health as judged by the Investigator

6. Subjects and parent(s)/legal guardian(s) are considered reliable and capable ofadhering to the Protocol and visit schedule, according to the judgment of theInvestigator.

Exclusion Criteria:

1. Subjects with any serious medical condition, clinically significant vital signs, orphysical examination abnormality that would prevent study participation or place thesubject at significant risk, as judged by the Investigator.

2. Subjects who have unstable AD or any consistent requirement for high potency topicalsteroids to manage AD signs or symptoms.

3. Subjects previously treated with ARQ-151

4. Subjects currently undergoing allergy testing or food challenges, or plan to do soduring the study.

5. Parent(s)/legal guardian(s) who are unable to communicate, read, or understand thelocal language. Subjects who display another condition, which in the Investigator'sopinion, makes them unsuitable for clinical study participation.

6. Subjects who are family members of the clinical study staff or sponsor.